Analysis on the selling price of vorasidenib-VORANIGO Lao version and its difference with the original drug

Vorasidenib (VORANIGO) is an oral IDH1/2 mutation-selective inhibitor, mainly used to treat gliomas and other related solid tumors with IDH1 or IDH2 mutations. The drug inhibits the abnormal metabolism and proliferation of tumor cells by inhibiting the activity of mutant isocitrate dehydrogenase (IDH) and reducing the accumulation of 2-hydroxyglutarate (2-HG). As a targeted therapy drug, vorsidenib has shown good anti-tumor potential in clinical practice, and is especially suitable for patients with IDH mutation-positive patients.

The original drug of Voxiranib is mainly produced in the United States overseas, with specifications of 40mg*30 tablets/ boxes. Each box sells for approximately 38 more than RMB (exchange rate fluctuations may cause price changes). Since it has not yet been launched in China, patients can only purchase the original drug through formal overseas channels. The high price makes original drugs a heavy financial burden for most patients. At the same time, attention must be paid to the formality and logistics safety of overseas drug purchases to ensure that the sources of drugs are reliable and the ingredients are safe.

There are also generic versions of Voxanib available in overseas markets, of which Voxanib of the same specification produced by Lucius Pharmaceuticals in Laos sells for about more than 7,000 yuan per box (exchange rate fluctuations may affect the price). The Lao version of generic drugs is basically the same as the original drug in terms of drug ingredients and active ingredients. The clinical efficacy is theoretically similar, but the price is significantly lower, providing a more accessible option for patients with limited financial conditions. The emergence of generic drugs can help alleviate the economic pressure caused by the high prices of original drugs while expanding the availability of drugs.

Generally speaking, there is not much difference in drug ingredients and efficacy between the original version of Voxanib and the Lao version of the generic drug, but there are significant differences in price and accessibility. Original drugs are expensive and are more suitable for patients seeking official drug sources, while Lao version of generic drugs has more advantages in price and is suitable for long-term use or patients with limited financial conditions. Clinically, patients should consider their financial affordability, reliability of drug sources and long-term treatment needs when choosing voroxiranib, and design individualized treatment plans under the guidance of professional doctors to ensure safe and effective use.

Reference link:https://www.drugs.com